Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy

Vassilis Dimas, Colby Ayers, James D Daniels, Jose A Joglar, Joseph A Hill, R. Haris Naseem

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Multiple pharmacological therapies currently in prevalent clinical use for cardiac diseases have antifibrotic properties. Spironolactone, a potent antifibrotic agent, is currently used for advanced heart failure. Therapies such as HMG-CoA reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) also have antifibrotic properties. However, the effect of these medications on the ventricular arrhythmia phenotype is currently unknown. Therefore, we set out to define the ventricular arrhythmia rates in patients actively treated with such therapies. Methods and Results: We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties. VT rates were significantly diminished in patients treated with spironolactone (158 ± 26 beats per minute [bpm], n = 21) compared to patients on no medications (205 ± 22 bpm, n = 13) or those who were on similar heart-failure therapies but not on spironolactone (186 ± 32 bpm, n = 82). In addition, we observed that VT rates showed a significant trend toward lower rates in patients receiving either statins or ACEi, compared to patients on no medical therapy. In multivariate analysis, spironolactone therapy was identified as the single most significant variable for reduced VT rate. Conclusion: Use of spironolactone in patients with heart failure is associated with reduced VT rate. Similar but less-significant reductions in VT rates were observed with use of other pharmacological agents with antifibrotic properties, such as statins and ACEi. Our findings, at least in part, could account for reduction in sudden cardiac death rates documented with use of these therapies. (PACE 2011; 34:309-314))

Original languageEnglish (US)
Pages (from-to)309-314
Number of pages6
JournalPACE - Pacing and Clinical Electrophysiology
Volume34
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Spironolactone
Ventricular Tachycardia
Cardiomyopathies
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Therapeutics
Cardiac Arrhythmias
Heart Diseases
Pharmacology
Sudden Cardiac Death
Multivariate Analysis
Phenotype
Mortality

Keywords

  • antifibrotic therapies
  • cardiomyopathy
  • electrophysiology
  • spironolactone
  • ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy. / Dimas, Vassilis; Ayers, Colby; Daniels, James D; Joglar, Jose A; Hill, Joseph A; Naseem, R. Haris.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 34, No. 3, 03.2011, p. 309-314.

Research output: Contribution to journalArticle

@article{114ab179775640668da5e080bc207f3e,
title = "Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy",
abstract = "Introduction: Multiple pharmacological therapies currently in prevalent clinical use for cardiac diseases have antifibrotic properties. Spironolactone, a potent antifibrotic agent, is currently used for advanced heart failure. Therapies such as HMG-CoA reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) also have antifibrotic properties. However, the effect of these medications on the ventricular arrhythmia phenotype is currently unknown. Therefore, we set out to define the ventricular arrhythmia rates in patients actively treated with such therapies. Methods and Results: We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties. VT rates were significantly diminished in patients treated with spironolactone (158 ± 26 beats per minute [bpm], n = 21) compared to patients on no medications (205 ± 22 bpm, n = 13) or those who were on similar heart-failure therapies but not on spironolactone (186 ± 32 bpm, n = 82). In addition, we observed that VT rates showed a significant trend toward lower rates in patients receiving either statins or ACEi, compared to patients on no medical therapy. In multivariate analysis, spironolactone therapy was identified as the single most significant variable for reduced VT rate. Conclusion: Use of spironolactone in patients with heart failure is associated with reduced VT rate. Similar but less-significant reductions in VT rates were observed with use of other pharmacological agents with antifibrotic properties, such as statins and ACEi. Our findings, at least in part, could account for reduction in sudden cardiac death rates documented with use of these therapies. (PACE 2011; 34:309-314))",
keywords = "antifibrotic therapies, cardiomyopathy, electrophysiology, spironolactone, ventricular tachycardia",
author = "Vassilis Dimas and Colby Ayers and Daniels, {James D} and Joglar, {Jose A} and Hill, {Joseph A} and Naseem, {R. Haris}",
year = "2011",
month = "3",
doi = "10.1111/j.1540-8159.2010.02888.x",
language = "English (US)",
volume = "34",
pages = "309--314",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy

AU - Dimas, Vassilis

AU - Ayers, Colby

AU - Daniels, James D

AU - Joglar, Jose A

AU - Hill, Joseph A

AU - Naseem, R. Haris

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: Multiple pharmacological therapies currently in prevalent clinical use for cardiac diseases have antifibrotic properties. Spironolactone, a potent antifibrotic agent, is currently used for advanced heart failure. Therapies such as HMG-CoA reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) also have antifibrotic properties. However, the effect of these medications on the ventricular arrhythmia phenotype is currently unknown. Therefore, we set out to define the ventricular arrhythmia rates in patients actively treated with such therapies. Methods and Results: We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties. VT rates were significantly diminished in patients treated with spironolactone (158 ± 26 beats per minute [bpm], n = 21) compared to patients on no medications (205 ± 22 bpm, n = 13) or those who were on similar heart-failure therapies but not on spironolactone (186 ± 32 bpm, n = 82). In addition, we observed that VT rates showed a significant trend toward lower rates in patients receiving either statins or ACEi, compared to patients on no medical therapy. In multivariate analysis, spironolactone therapy was identified as the single most significant variable for reduced VT rate. Conclusion: Use of spironolactone in patients with heart failure is associated with reduced VT rate. Similar but less-significant reductions in VT rates were observed with use of other pharmacological agents with antifibrotic properties, such as statins and ACEi. Our findings, at least in part, could account for reduction in sudden cardiac death rates documented with use of these therapies. (PACE 2011; 34:309-314))

AB - Introduction: Multiple pharmacological therapies currently in prevalent clinical use for cardiac diseases have antifibrotic properties. Spironolactone, a potent antifibrotic agent, is currently used for advanced heart failure. Therapies such as HMG-CoA reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) also have antifibrotic properties. However, the effect of these medications on the ventricular arrhythmia phenotype is currently unknown. Therefore, we set out to define the ventricular arrhythmia rates in patients actively treated with such therapies. Methods and Results: We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties. VT rates were significantly diminished in patients treated with spironolactone (158 ± 26 beats per minute [bpm], n = 21) compared to patients on no medications (205 ± 22 bpm, n = 13) or those who were on similar heart-failure therapies but not on spironolactone (186 ± 32 bpm, n = 82). In addition, we observed that VT rates showed a significant trend toward lower rates in patients receiving either statins or ACEi, compared to patients on no medical therapy. In multivariate analysis, spironolactone therapy was identified as the single most significant variable for reduced VT rate. Conclusion: Use of spironolactone in patients with heart failure is associated with reduced VT rate. Similar but less-significant reductions in VT rates were observed with use of other pharmacological agents with antifibrotic properties, such as statins and ACEi. Our findings, at least in part, could account for reduction in sudden cardiac death rates documented with use of these therapies. (PACE 2011; 34:309-314))

KW - antifibrotic therapies

KW - cardiomyopathy

KW - electrophysiology

KW - spironolactone

KW - ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=79952466122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952466122&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.2010.02888.x

DO - 10.1111/j.1540-8159.2010.02888.x

M3 - Article

VL - 34

SP - 309

EP - 314

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 3

ER -